Stereotaxis Reports Fourth Quarter 2008 Financi... (08 totaled $30.4 million comparedto $23....)

Stereotaxis Reports Fourth Quarter 2008 Financial Results

Date:2/26/2009

08 totaled $30.4 million, compared to $23.7 million at December 31, 2007.

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Standard Time today to discuss its financial results for the fourth quarter. To access the conference call, please dial (800) 240-2134. International participants can call (303) 275-2170. An audio replay of the call will be available for seven days following the call at (800) 405-2236 for U.S. callers or (303) 590- 3000 for those calling outside the U.S. The password required to access the replay is 11125670#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=55849

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire
2. Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants
3. Stereotaxis Reports Third Quarter 2008 Financial Results
4. Stereotaxis Announces New Management Appointment
5. Stereotaxis Reports Record Second Quarter Revenue
6. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
7. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
8. Stereotaxis Reports Record First Quarter Orders
9. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
10. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
11. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe

Post Your Comments:

(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...

(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...

(Date:5/22/2013)... Following the success of last year’s ... Fit Body Boot Camp Kincardine has announced it will ... starting on June 3rd at its Kincardine fitness ... Kincardine, Ontario. , Fit Body Boot Camp’s 1,000 lb. ... community residents to lose a total of 1,000 pounds ...

(Date:5/22/2013)... Jersey City, NJ (PRWEB) May 22, 2013 ... governance, compliance, and management solutions for social enterprise ... Partners, LLC, a consulting firm based in Chicago, ... to integrate their products and provide best-in-class solutions ... productivity and improve collaboration. , AvePoint’s DocAve ...

(Date:5/22/2013)... adherence to appropriate medication therapy has been shown to ... 125,000 deaths in the U.S. every year are attributed ... estimated that between 33% and 69% of all medication-related ... a reality that costs the American health-care system approximately ... degree of medication non-adherence — and the consequences therefrom ...

Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2

[0] Registry questions superiority of bivalirudin over heparin [0] Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity [0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance

... 25 Former NFL player and Dallas Cowboy,Jason Kaiser ... graduation ceremony. Kaiser earned the title of,valedictorian with a ... people in,this school and in my class especially," he ... Before enrolling in Parker College, Kaiser played professional football,for ...

... protein levels could key future treatments for Alzheimer,s , , ... finds that where protein-destroying machines reside in the brain,s ... a finding that may play a role in future ... Wake Forest University School of Medicine researchers studying mice ...

... his left eyebrow was possibly skin cancer , , FRIDAY, ... during his lifetime, historians have gone to great lengths ... of Franklin Delano Roosevelt, the 32nd president of the ... and heart disease is now well-documented. But a new ...

... QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial results ... otherwise, all amounts are in U.S. dollars,and in accordance ... 2008, we were pleased to report the U.S. Food,and ... blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, President ...

... Inc., (a wholly owned,subsidiary of Mentice AB), a ... the field of medicine, has recently appointed,Jeff Sirek ... Clinical,Applications Manager for the Americas., Jeff Sirek ... years with GE Healthcare in its Cardiovascular Ultrasound,Division ...

... Solutions, Inc. announced,today the addition of Dr. Marc ... serve as Vice President of Research and Development ... of spine,system/orthopedic development experience, most recently having directed,development ... Marc to Facet Solutions bolsters an already great,team, ...

Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate When It Comes to Memory, It's All About Location FDR Might Have Had Melanoma QLT announces first quarter results for 2008 Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.Facet Solutions, Inc. Expands Executive Management Team

(Date:5/22/2013)... , May 22, 2013 PRNewswire – ... production of a vaccine candidate for the newly ... party laboratory using the iBioLaunch™ platform. This validation ... from initial antigen sequence information to purification of ... ) The iBioLaunch platform eliminates ...

(Date:5/22/2013)... WomanCare Global recently launched Simplant in ... training initiative attended by 90 health care providers. ... http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) Simplant, a long-acting ... subdermal implant composed of two thin, flexible, silicone ... form of the hormone progestin). These are inserted ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

[0] iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza [0] WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile [0] Concord Medical Reports First Quarter 2013 Financial Results

... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...

... 17 Dendreon Corporation,(Nasdaq: DNDN ) today ... study,of NEUVENGE, an investigational active cellular immunotherapy, in ... Oncology. The article highlights,the safety profile, immune response ... breast cancer who have failed standard,therapy. "In ...

Cached Medicine Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Netromycin, Random Level Netilmicin, Random Level Neopterin Level Neonatal 5 Drug Panel, Meconium